Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.

Article  PubMed  Google Scholar 

Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–88. https://doi.org/10.1038/s41575-020-0310-z.

Article  PubMed  PubMed Central  Google Scholar 

Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–85. https://doi.org/10.1148/radiol.2422051113.

Article  PubMed  Google Scholar 

Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol. 2014;49:46–56. https://doi.org/10.1007/s00535-013-0790-5.

Article  CAS  PubMed  Google Scholar 

Park JW, Ji HK, Seok KK, Keon WK, Kyung WP, Choi J Il, et al. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912–21. https://doi.org/10.2967/jnumed.108.055087

Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. 68Ga-FAPI-04 versus 18F-FDG PET/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021;11:1–10. https://doi.org/10.3389/fonc.2021.693640.

Article  Google Scholar 

Rettig WJ, Chesa PG, Beresford HR, Feickert HJ, Jennings MT, Cohen J, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets1. Cancer Res. 1986;46:6406–12.

CAS  PubMed  Google Scholar 

Boulter L, Bullock E, Mabruk Z, Brunton VG. The fibrotic and immune microenvironments as targetable drivers of metastasis. Br J Cancer. 2021;124:27–36. https://doi.org/10.1038/s41416-020-01172-1.

Article  PubMed  Google Scholar 

Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115. https://doi.org/10.1038/s41573-018-0004-1.

Article  CAS  PubMed  Google Scholar 

Wang L, Tang G, Hu K, Liu X, Zhou W, Li H, et al. Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Evaluation of Advanced Lung Cancer. Radiology. 2022;303:191–9. https://doi.org/10.1148/radiol.211424.

Article  PubMed  Google Scholar 

Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. J Nucl Med. 2022;63:81–8. https://doi.org/10.2967/jnumed.120.258467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944–55. https://doi.org/10.1007/s00259-020-05146-6.

Article  CAS  PubMed  Google Scholar 

Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging. 2021;48:196–203. https://doi.org/10.1007/s00259-020-04882-z.

Article  PubMed  Google Scholar 

Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593–603. https://doi.org/10.1007/s00259-020-05070-9.

Article  CAS  PubMed  Google Scholar 

Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [18F] AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761–73. https://doi.org/10.1007/s00259-022-05758-0.

Article  CAS  PubMed  Google Scholar 

Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49:2833–43. https://doi.org/10.1007/s00259-021-05646-z.

Article  CAS  PubMed  Google Scholar 

Wang S, Zhou X, Xu X, Ding J, Liu S, Hou X, et al. Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. Eur J Nucl Med Mol Imaging. 2021;48:4259–71. https://doi.org/10.1007/s00259-021-05470-5.

Article  CAS  PubMed  Google Scholar 

Fu L, Huang S, Wu H, Dong Y, Xie F, Wu R, et al. Superiority of [68Ga]Ga-FAPI-04/ [18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022;32:6281–90. https://doi.org/10.1007/s00330-022-08743-1.

Article  CAS  PubMed  Google Scholar 

Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased 18F-FDG uptake. J Nucl Med. 2005;46:1753–9.

CAS  PubMed  Google Scholar 

Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333–9.

CAS  PubMed  Google Scholar 

Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Higuchi T, Miyakubo M, et al. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med. 2008;22:83–6. https://doi.org/10.1007/s12149-007-0076-1.

Article  PubMed  Google Scholar 

Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343–57. https://doi.org/10.1038/s41388-018-0275-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505. https://doi.org/10.1038/s41575-020-0300-1.

Article  PubMed  PubMed Central  Google Scholar 

Gieniec KA, Butler LM, Worthley DL, Woods SL. Cancer-associated fibroblasts—heroes or villains? Br J Cancer. 2019;121:293–302. https://doi.org/10.1038/s41416-019-0509-3.

Article  PubMed  PubMed Central  Google Scholar 

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E. In search of definitions: cancer-associated fibroblasts and their markers. Int J Cancer. 2020;146:895–905. https://doi.org/10.1002/ijc.32193.

Article  CAS  PubMed  Google Scholar 

Sharma P, Singh SS, Gayana S. Fibroblast activation protein inhibitor PET/CT: a promising molecular imaging Tool. Clin Nucl Med. 2021;46:e141–50. https://doi.org/10.1097/RLU.0000000000003489.

Article  PubMed  Google Scholar 

Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583–94. https://doi.org/10.1016/j.jhep.2013.03.033.

Article  CAS  PubMed  Google Scholar 

Luo Y, Pan Q, Yang H, Peng L, Zhang W, Li F. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI for imaging igg4-related disease: comparison to 18F-FDG PET/CT. J Nucl Med. 2021;62:266–71. https://doi.org/10.2967/jnumed.120.244723.

Article  CAS  PubMed  Google Scholar 

Zhao L, Gu J, Fu K, Lin Q, Chen H. 68Ga-FAPI PET/CT in assessment of liver nodules in a cirrhotic patient. Clin Nucl Med. 2020;45:e430–2. https://doi.org/10.1097/RLU.0000000000003015.

Article  PubMed  Google Scholar 

Grazioli L, Ambrosini R, Frittoli B, Grazioli M, Morone M. Primary benign liver lesions: Benign focal liver lesions can origin from all kind of liver cells: hepatocytes, mesenchymal and cholangiocellular line. Eur J Radiol. 2017;59:583–94. https://doi.org/10.1016/j.ejrad.2017.08.028.

Article  Google Scholar 

Ehman EC, Torbenson MS, Wells ML, Welch BT, Thompson SM, Garg I, et al. Hepatic tumors of vascular origin: imaging appearances. Abdom Radiol. Springer US; 2018;43:1978–90. https://doi.org/10.1007/s00261-017-1401-3

Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62. https://doi.org/10.1056/NEJMra1713263.

Article  CAS  PubMed  Google Scholar 

Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12:1–15. https://doi.org/10.1186/s13045-019-0770-1.

Article  CAS  Google Scholar 

Wang XM, Yu DMT, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 2005;42:935–45. https://doi.org/10.1002/hep.20853.

Article  CAS  PubMed  Google Scholar 

Pirasteh A, Periyasamy S, Meudt JJ, Lui Y, Lee LM, Schachtschneider KM, et al. Staging liver fibrosis by fibroblast activation protein inhibitor positron emission tomography in a human-sized swine model. J Nucl Med. 2022;jnumed.121.263736. https://doi.org/10.2967/jnumed.121.263736